VC: Novacea garners $25M

Novacea leads with $25 million in third round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Novacea South San Francisco

$25M third round

Apax Partners

The funding is earmarked to launch a Phase III clinical trial of DN-101 in advanced prostate cancer.

Xytis London

$24.5M second round

Sanderling Ventures

The money will go to preclinical and Phase I and II studies of experimental therapies for CNS disorders.

Tioga Pharmaceuticals San Diego

$24M first round

Forward Ventures

The company has plans to advance a new therapy into Phase IIa and IIb for asimadoline.

CanBas Japan

$20M fourth round

NIF SMBC Ventures

CBP501 is currently under investigation in Phase I as a G2 checkpoint blocker.

Athenix Durham, NC

$13M third round

Finistere Partners

Athenix will use proceeds to continue moving products from their portfolio through field trials to registration.

EraGen Biosciences Madison, WI

$12M first round

First Analysis Corporation

EraGen is currently engaged in molecular diagnostics.

Cetek Marlborough, MA

$10M fifth round

Argonaut Private Equity

The funding will advance the company's drug discovery platform and bolster its emerging pipeline of compounds to treat cancer, HIV and Hepatitis C.

Hawaii Biotech Aiea, Hawaii

$7.8M third round

Board Chairman Nick Mitsakos

The company has been developing an anti-inflammatory compound.